Efficacy and safety of new drugs for induction, autologous stem cell transplantation, consolidation and maintenance therapy in patients with newly diagnosed elderly symptomatic multiple myeloma: phase 2 study FBMTG EMM17

Trial Profile

Efficacy and safety of new drugs for induction, autologous stem cell transplantation, consolidation and maintenance therapy in patients with newly diagnosed elderly symptomatic multiple myeloma: phase 2 study FBMTG EMM17

Recruiting
Phase of Trial: Phase II

Latest Information Update: 04 Oct 2017

At a glance

  • Drugs Bortezomib (Primary) ; Ixazomib (Primary) ; Lenalidomide (Primary) ; Dexamethasone; Plerixafor
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Acronyms FBMTG EMM17
  • Most Recent Events

    • 04 Oct 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top